Cost Utility Analysis Of Aflibercept, Ranibizumab, And Bevacizumab For The Treatment Of Neovascular Age-Related Macular Degeneration
May 1, 2014, 00:00
10.1016/j.jval.2014.03.1670
https://www.valueinhealthjournal.com/article/S1098-3015(14)01721-5/fulltext
Title :
Cost Utility Analysis Of Aflibercept, Ranibizumab, And Bevacizumab For The Treatment Of Neovascular Age-Related Macular Degeneration
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(14)01721-5&doi=10.1016/j.jval.2014.03.1670
First page :
A287
Section Title :
Sensory Systems Disorders
Open access? :
No
Section Order :
1161